Immune Correlates of Protection Against SARS-CoV-2 in the Setting of HIV Infection
Tracks
x
x
| Friday, April 29, 2022 |
| 4:30 PM - 5:45 PM |
Overview
Corrélats immuns de protection contre le SARS-CoV-2 dans l’installation de l’infection au VIH
Details
COVID-19 has claimed the lives of millions of people worldwide, has had dramatic negative impacts of healthcare systems and devastated the global economy. The speed at which preventative vaccines against SARS-CoV-2 have been deployed has been unprecedented. Anti-viral immunity induced by infection with SARS-CoV-2 or vaccination reduce the risk of infection or re-infection while viral variants with resistance to these immune responses continue to be selected for in areas with low vaccination rates and have rapidly spread. The failure of our immune system to prevent SARS-CoV-2 infections either because of waning immunity or emergence of viral variants that circumvent anti-viral immunity is the basis for recurring waves of infection that cause a range of disease severity, death and the instigation of public health measures with dramatic impacts on our lives. This session will call upon a panel of researchers and clinician scientist to discuss what we currently know about what virus- or vaccine-induced immune responses constitute correlates of protection, their durability, and interactions with HIV infection.
Learning Objectives:
1. Review what we know about protective immune responses to SARS-CoV-2
2. Review Canada’s response to the SARS-CoV-2 pandemic
Moderator: Matt Miller, McMaster University
Panelists:
Céclie Tremblay , CRCHUM
Andrés Finzi, CRCHUM
Samira Mubareka, Sunnybrook Hospital
Galit Alter, Harvard Medical School
Darryl Falzarano, VIDO
Speaker
Cecile Tremblay
Full Professor of Microbiology, Infectious Diseases and Immunology
Centre Hospitalier de l'universite de Montreal
Special Session II
Abstract
COVID-19 has claimed the lives of millions of people worldwide, has had dramatic negative impacts of healthcare systems and devastated the global economy. The speed at which preventative vaccines against SARS-CoV-2 have been deployed has been unprecedented. Anti-viral immunity induced by infection with SARS-CoV-2 or vaccination reduce the risk of infection or re-infection while viral variants with resistance to these immune responses continue to be selected for in areas with low vaccination rates and have rapidly spread. The failure of our immune system to prevent SARS-CoV-2 infections either because of waning immunity or emergence of viral variants that circumvent anti-viral immunity is the basis for recurring waves of infection that cause a range of disease severity, death and the instigation of public health measures with dramatic impacts on our lives. This session will call upon a panel of researchers and clinician scientist to discuss what we currently know about what virus- or vaccine-induced immune responses constitute correlates of protection, their durability, and interactions with HIV infection.
Learning Objectives:
1. Review what we know about protective immune responses to SARS-CoV-2
2. Review Canada’s response to the SARS-CoV-2 pandemic
Learning Objectives:
1. Review what we know about protective immune responses to SARS-CoV-2
2. Review Canada’s response to the SARS-CoV-2 pandemic
